Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.51 |
| ▸ | RXRB | P28702 | 8/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 8/20 | 0.44 |
| ▸ | RARB | P10826 | 7/20 | 0.44 |
| ▸ | RARG | P13631 | 7/20 | 0.44 |
| ▸ | RARA | P10276 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | BLVRB | P30043 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615150 | 0.83 | RXRA (0.58) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL1615798 | 0.78 | CYP3A4 (0.51) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL1616060 | 0.75 | RAB9A (0.48) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL1616205 | 0.75 | CYP3A4 (0.51) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL1615388 | 0.74 | RARB (0.64) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL8839185 | 0.74 | RXRA (0.62) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL4419817 | 0.73 | CYP26A1 (0.50) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL1615210 | 0.73 | RARA (0.53) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL6147894 | 0.72 | RXRA (0.64) | RXRARXRBCYP26A1RARBRARG | |
| SCHEMBL1615253 | 0.72 | CYP26A1 (0.60) | RXRARXRBCYP26A1RARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923579-B2 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2011-04-12 | — | — | US | disclosed |
| US-7923579-B2 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2011-04-12 | — | — | US | disclosed |
| US-7923579-B2 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2011-04-12 | — | — | US | disclosed |
| EP-1692097-B1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1692097-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | Exonhit Therapeutics SA (FR) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058803-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058803-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2005-06-30 | — | — | WO | disclosed |
| EP-1541549-A1 | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods | Exonhit Therapeutics S.A. (FR) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | HDAC5, HDAC1, HDAC2 | RXRA 1796/4885RXRB 2026/4885CYP26A1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.